These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9604911)

  • 1. Clinical trial assessment of lipid-acting drugs in diabetic patients.
    Steiner G
    Am J Cardiol; 1998 Apr; 81(8A):58F-59F. PubMed ID: 9604911
    [No Abstract]   [Full Text] [Related]  

  • 2. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
    Davidson MH
    Curr Atheroscler Rep; 2003 Sep; 5(5):418-22. PubMed ID: 12911853
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating lipid abnormalities in patients with type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2001 Dec; 88(12A):37N-40N. PubMed ID: 11788129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclusion of lipoprotein subfractions among efficacy parameters.
    Superko HR
    Am J Cardiol; 1998 Apr; 81(8A):52F-55F. PubMed ID: 9604909
    [No Abstract]   [Full Text] [Related]  

  • 5. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
    Yoshino G; Hirano T; Kazumi T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
    [No Abstract]   [Full Text] [Related]  

  • 6. New strategies for the treatment of diabetic dyslipidemia.
    Haffner SM; Goldberg RB
    Diabetes Care; 2002 Jul; 25(7):1237-9. PubMed ID: 12087025
    [No Abstract]   [Full Text] [Related]  

  • 7. Coronary artery disease and diabetes.
    Bohannon NJ
    Postgrad Med; 1999 Feb; 105(2):66-8, 71-2, 77-80. PubMed ID: 10026704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis by the Program on the Surgical Control of the Hyperlipidemias (POSCH) investigators.
    Gould AL; Cariski AT
    Ann Surg; 1998 Feb; 227(2):314-6. PubMed ID: 9488536
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of lipids and type 2 diabetes.
    Hermayer KL
    Curr Cardiol Rep; 2004 Nov; 6(6):443-50. PubMed ID: 15485606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of lipid disorders in diabetes mellitus.
    Lopes-Virella MF; Colwell JA
    Diabetes Metab Rev; 1987 Jul; 3(3):691-722. PubMed ID: 3608755
    [No Abstract]   [Full Text] [Related]  

  • 11. Specific lipid lowering therapy in the management of diabetes.
    Durrington PN
    Postgrad Med J; 1991 Oct; 67(792):947-52. PubMed ID: 1758809
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes of lipid-lowering treatment in postmenopausal women.
    LaRosa JC
    Drugs Aging; 2002; 19(8):595-604. PubMed ID: 12207553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipids and atherogenesis in diabetes mellitus.
    Betteridge DJ
    Atherosclerosis; 1996 Jul; 124 Suppl():S43-7. PubMed ID: 8831915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
    Nakamura T; Kodama Y; Takano H; Umetani K; Fujioka D; Saito Y; Kawabata K; Obata JE; Kitta Y; Kobayashi T; Mende A; Kugiyama K
    Atherosclerosis; 2007 Aug; 193(2):449-51. PubMed ID: 16997309
    [No Abstract]   [Full Text] [Related]  

  • 15. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 16. Trials of lipid-lowering therapy in primary prevention of coronary heart disease.
    Jones PH
    Curr Opin Lipidol; 1995 Dec; 6(6):365-8. PubMed ID: 8750249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [KLAS [Kanazawa Lipid Assessment Survey]].
    Mabuchi H; Inazu A; Higashikata T; Nohara A; Koizumi J
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():469-76. PubMed ID: 11347115
    [No Abstract]   [Full Text] [Related]  

  • 18. [Statins (HMG-CoA reductase inhibitors)].
    Gotoda T
    Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
    Shepherd J; Olsson AG; Sacks FM; Black DM; Orloff DG; Bilheimer DW
    Am J Cardiol; 1998 Apr; 81(8A):88F-94F. PubMed ID: 9604922
    [No Abstract]   [Full Text] [Related]  

  • 20. The antilipemic effectiveness of aluminium clofibrate on hyperlipidemic patients with or without diabetes mellitus.
    Lam HC; Li SH; Wang JT; Tang KT; Ho LT
    Zhonghua Yi Xue Za Zhi (Taipei); 1987 Nov; 40(5):463-70. PubMed ID: 3332236
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.